{"id":8682,"date":"2026-10-26T11:41:45","date_gmt":"2026-10-26T06:11:45","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/neulandlab-share-price-today-2026-10-26\/"},"modified":"2026-10-26T17:26:04","modified_gmt":"2026-10-26T11:56:04","slug":"neulandlab-share-price-today-2026-10-26","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/neulandlab-share-price-today-2026-10-26\/","title":{"rendered":"Neuland Laboratories Share Price Today: Why NEULANDLAB Is Rising 1.01% | 26 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: NEULANDLAB<\/strong> \u00b7 26 October 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b919,055.00<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>+1.01%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b919,210.00 \/ \u20b918,485.00<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b918,865.00<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>25,080<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>26 October 2026 \u00b7 03:25 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Neuland Laboratories Ltd. (NEULANDLAB) moved higher in Monday&#x27;s session, gaining 1.01% to close at \u20b919,055.00 after opening lower at \u20b918,485.00. The stock traded within a day&#x27;s range of \u20b918,485.00 to \u20b919,210.00, reflecting some intraday volatility.<\/li>\n<li>Neuland Laboratories informed the exchanges that the US FDA issued an Establishment Inspection Report (EIR) for the inspection conducted at its Unit 3 manufacturing facility in Sangareddy District between August 10 and August 14, 2026. The regulatory authority has officially concluded that the inspection is closed, following the company&#x27;s response to earlier observations regarding procedural monitoring.<\/li>\n<li>Trading volume was 0.52 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is Neuland Laboratories share price rising on 26 October 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Neuland Laboratories Ltd. (NEULANDLAB) moved higher in Monday&#x27;s session, gaining 1.01% to close at \u20b919,055.00 after opening lower at \u20b918,485.00. The stock traded within a day&#x27;s range of \u20b918,485.00 to \u20b919,210.00, reflecting some intraday volatility.<\/p>\n<p class=\"wt-copy\">The broader market and healthcare sector witnessed positive momentum during the session, with the Nifty advancing 0.68% and the sector benchmark Nifty Pharma rising 1.76%. Neuland Laboratories participated in this broader upward trend, though its 1.01% gain lagged the stronger sectoral benchmark performance. On a broader timeframe, the stock has experienced recent corrections, registering a 5-day return of -3.15% and a 20-day return of -13.01% from its 52-week high of \u20b924,225.00.<\/p>\n<p class=\"wt-copy\">Recent company developments provide longer-term operational context rather than a direct trigger for today&#x27;s price action. Notably, the US FDA concluded its inspection of the company&#x27;s Unit 3 manufacturing facility as &#x27;closed&#x27; following the issuance of an Establishment Inspection Report in October 2026. Additionally, the company recently commenced commercial operations at its first peptide manufacturing module following a $30 million investment, expanding its capacity for complex Active Pharmaceutical Ingredients.<\/p>\n<p class=\"wt-copy\">25,080 shares traded by 26 October 2026 \u00b7 03:25 PM IST. This compares with a 20-day average daily volume of 48,114 shares (0.52 times). The five-day average daily volume was 42,476 shares. Separately, the NSE report for 23 October 2026 showed 25,786 shares delivered, representing 48.34% of that day\u2019s traded volume. The same report recorded 22,618 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>technical rebound following recent sector-aligned buying<\/strong><\/p>\n<p class=\"wt-copy\">Today&#x27;s 1.01% advance lacks a single confirmed corporate catalyst from the trading session, occurring alongside positive broader pharma sector momentum and light trading volumes at 0.52 times the 20-day average.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">US FDA Concludes Unit 3 Inspection as Closed<\/div>\n<div class=\"wt-card-date\">14 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Neuland Laboratories informed the exchanges that the US FDA issued an Establishment Inspection Report (EIR) for the inspection conducted at its Unit 3 manufacturing facility in Sangareddy District between August 10 and August 14, 2026. The regulatory authority has officially concluded that the inspection is closed, following the company&#x27;s response to earlier observations regarding procedural monitoring.<\/p>\n<p class=\"wt-copy\">Successful closure of regulatory inspections removes compliance overhangs and ensures smooth operational and export capabilities for key manufacturing facilities.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">First Commercial Peptide Module Commences Operations<\/div>\n<div class=\"wt-card-date\">15 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The company announced that the first of four scheduled modules has commenced operations at its commercial peptide manufacturing site, backed by a $30 million investment. The new module provides 7,000L of total reactor capacity and supports flexible customer programmes for complex and long-chain peptide APIs.<\/p>\n<p class=\"wt-copy\">Expanding dedicated peptide manufacturing capacity directly supports the company&#x27;s growth strategy in high-value, complex molecules amid rising global customer demand.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/NEULANDLAB_15092026102537_SignedSEIntimation15092026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Board Approves Capex for Kakinada Land Acquisition<\/div>\n<div class=\"wt-card-date\">7 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Neuland Laboratories announced that its Board of Directors approved a capital expenditure of \u20b9126 crores to purchase approximately 134 acres of land at Auro Industrial City in Kakinada, Andhra Pradesh. The company also secured a right of first refusal for an additional contiguous parcel of approximately 66 acres for future expansions.<\/p>\n<p class=\"wt-copy\">Securing a large land parcel lays the strategic foundation for long-term manufacturing capacity enhancements beyond immediate operational footprints.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/NEULANDLAB_07092026172307_SignedSEIntimation_Final.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Earnings \/ operating update<\/div>\n<div class=\"wt-card-date\">5 August 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated August 05, 2026, titled &quot;Press Release on the Financial Results of the Company for the quarter ended June 30, 2026&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/NEULANDLAB_05082026161549_SignedPressRelease.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Company update<\/div>\n<div class=\"wt-card-date\">15 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">&#x27;We refer to our letter dated August 14, 2026 regarding the US FDA inspection conducted at our Unit 3 manufacturing facility and would like to inform that the US FDA has issued an EIR against the inspection conducted from August 10, 2026 to August 14, 2026. The US FDA has concluded that this inspection is closed.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/NEULANDLAB_14102026214251_SignedSEIntimation14102026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">32.26%<\/div>\n<div class=\"wt-note\">32.62% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">21.93%<\/div>\n<div class=\"wt-note\">21.08% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">38.19%<\/div>\n<div class=\"wt-note\">37.59% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1736092_12102026034744_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"insider\" style=\"background:#edf5ff;border:1px solid #c9dbef;border-left:4px solid #4b7fb8;border-radius:10px\">\n<div class=\"wt-card-title\">Historical Insider Activity<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>Davuluri Saharsh Rao<\/strong><span class=\"wt-note\">Promoters<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Pledge<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>96,000 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>25 March 2026<\/strong><\/div>\n<\/div>\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>Deepthi Davuluri<\/strong><span class=\"wt-note\">Promoter Group<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Buy<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>12,500 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>4 March 2026<\/strong><\/div>\n<\/div>\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>Davuluri Saharsh Rao<\/strong><span class=\"wt-note\">Promoters<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Sell<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>12,500 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>4 March 2026<\/strong><\/div>\n<\/div>\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>Mr. Gannabathula Venkata Krishna Rama Rao<\/strong><span class=\"wt-note\">Promoters<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Sell<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>6,000 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>17 December 2025<\/strong><\/div>\n<\/div>\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>Ms. Kamala Tayaramma Kommula<\/strong><span class=\"wt-note\">Promoter Group<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Buy<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>6,000 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>17 December 2025<\/strong><\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">Source: NSE transaction disclosures. These are dated historical transactions.<\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 12.45% on 30 September 2026. This compares with 12.66% on 30 June 2026, a change of -0.21 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 34 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">HDFC MUTUAL FUND &#8211; HDFC MNC FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">3.62 lakh shares \u00b7 2.82%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">HSBC MUTUAL FUND &#8211; HSBC SMALL CAP FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">1.99 lakh shares \u00b7 1.55%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">ICICI PRUDENTIAL S&amp;P BSE 500 ETF<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">1.96 lakh shares \u00b7 1.53%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1736092_12102026034744_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>Research &amp; Brokerage Views<\/h2>\n<div class=\"wt-grid wt-grid-brokerage\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Goldman Sachs<\/div>\n<div class=\"wt-card-date\">13 May 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-broker-facts\"><span><span class=\"wt-label\">Rating<\/span><strong>Buy<\/strong><\/span><\/div>\n<p class=\"wt-copy\">Retained a positive stance following quarterly financial performance that exceeded consensus estimates.<\/p>\n<div class=\"wt-note wt-source-note\">Attributed brokerage opinion; not a WittyTrades recommendation.<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>Historical Bulk \/ Block Deals<\/h2>\n<div class=\"wt-grid wt-grid-cards\">\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">HDFC MUTUAL FUND<\/div>\n<div class=\"wt-card-date\">6 August 2026<\/div>\n<div class=\"wt-card-body\">Buy \u00b7 64,547 shares \u00b7 \u20b921,585.00<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Upcoming financial results for the quarter and half year ended September 30, 2026, scheduled for board review on November 3, 2026.<\/li>\n<li>Progress on execution and customer onboarding for the newly operational first commercial peptide manufacturing module.<\/li>\n<li>Further updates regarding capital expenditure execution and development plans for the newly acquired land parcel in Kakinada.<\/li>\n<li>Volume participation and delivery trends relative to the 20-day average volume of approximately 48k-50k equivalent daily levels.<\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/neulandlab\/\">More Neuland Laboratories news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Neuland Laboratories company news?<\/h3>\n<p class=\"wt-copy\">Neuland Laboratories informed the exchanges that the US FDA issued an Establishment Inspection Report (EIR) for the inspection conducted at its Unit 3 manufacturing facility in Sangareddy District between August 10 and August 14, 2026. The regulatory authority has officially concluded that the inspection is closed, following the company&#x27;s response to earlier observations regarding procedural monitoring.<\/p>\n<h3>How strong was Neuland Laboratories\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">25,080 shares traded, 0.52 times the 20-day average daily volume. The price and volume data are dated 26 October 2026 \u00b7 03:25 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@type\": \"WebSite\", \"@id\": \"https:\/\/www.wittytrades.com\/#website\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"name\": \"WittyTrades\", \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"inLanguage\": \"en-IN\"}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#organization\", \"name\": \"WittyTrades\", \"alternateName\": \"Witty Networks\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"telephone\": \"+91-22-48972020\", \"identifier\": [{\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}, {\"@type\": \"PropertyValue\", \"propertyID\": \"BSE Research Analyst Code\", \"value\": \"5430\"}]}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"parentOrganization\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}}, {\"@type\": \"Person\", \"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"worksFor\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}}, {\"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/neulandlab-share-price-today-2026-10-26\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/neulandlab-share-price-today-2026-10-26\/\"}, \"headline\": \"Neuland Laboratories Share Price Today: Why NEULANDLAB Is Rising 1.01% | 26 October 2026\", \"description\": \"Neuland Laboratories share price rose 1.01% to \u20b919,055.00 today. See why NEULANDLAB is rising, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-10-26T06:11:45Z\", \"dateModified\": \"2026-10-26T17:25:56.616457+05:30\", \"author\": {\"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\"}, \"reviewedBy\": {\"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\"}, \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"isPartOf\": {\"@id\": \"https:\/\/www.wittytrades.com\/#website\"}, \"about\": {\"@type\": \"Thing\", \"name\": \"Neuland Laboratories\", \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"NSE Symbol\", \"value\": \"NEULANDLAB\"}}, \"inLanguage\": \"en-IN\", \"isAccessibleForFree\": true, \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/neulandlab-company-news-2026-10-26.jpg\"]}]}<\/script><!-- wt-article-record:{\"news_events\":[{\"summary\":\"a press release dated August 05, 2026, titled \\\"Press Release on the Financial Results of the Company for the quarter ended June 30, 2026\\\".\",\"category\":\"Press Release\",\"date\":\"05-Aug-2026 16:16:30\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/NEULANDLAB_05082026161549_SignedPressRelease.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"Neuland Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"05-Aug-2026 16:03:18\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/NEULANDLAB_05082026155912_SignedSEIntimation.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"'We refer to our letter dated August 14, 2026 regarding the US FDA inspection conducted at our Unit 3 manufacturing facility and would like to inform that the US FDA has issued an EIR against the inspection conducted from August 10, 2026 to August 14, 2026. The US FDA has concluded that this inspection is closed.\",\"category\":\"Updates\",\"date\":\"14-Oct-2026 21:43:33\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/NEULANDLAB_14102026214251_SignedSEIntimation14102026.pdf\",\"headline\":\"Company update\",\"impact\":\"This is a recent company development worth monitoring. It should not automatically be treated as the sole cause of today's price move.\",\"importance_score\":2,\"completeness_score\":3},{\"summary\":\"30 of SEBI Listing Regulations - Execution of deed of Corporate Guarantee.\",\"category\":\"Giving guarantees\/indemnity\/ becoming a surety for third party\",\"date\":\"05-Aug-2026 16:30:58\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/NEULANDLAB_05082026163040_SignedSEIntimation.pdf\",\"headline\":\"Company update\",\"impact\":\"This is a recent company development worth monitoring. It should not automatically be treated as the sole cause of today's price move.\",\"importance_score\":2,\"completeness_score\":3}],\"recent_news\":[{\"summary\":\"a press release dated August 05, 2026, titled \\\"Press Release on the Financial Results of the Company for the quarter ended June 30, 2026\\\".\",\"category\":\"Press Release\",\"date\":\"05-Aug-2026 16:16:30\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/NEULANDLAB_05082026161549_SignedPressRelease.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"Neuland Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"05-Aug-2026 16:03:18\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/NEULANDLAB_05082026155912_SignedSEIntimation.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"'We refer to our letter dated August 14, 2026 regarding the US FDA inspection conducted at our Unit 3 manufacturing facility and would like to inform that the US FDA has issued an EIR against the inspection conducted from August 10, 2026 to August 14, 2026. The US FDA has concluded that this inspection is closed.\",\"category\":\"Updates\",\"date\":\"14-Oct-2026 21:43:33\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/NEULANDLAB_14102026214251_SignedSEIntimation14102026.pdf\",\"headline\":\"Company update\",\"impact\":\"This is a recent company development worth monitoring. It should not automatically be treated as the sole cause of today's price move.\",\"importance_score\":2,\"completeness_score\":3},{\"summary\":\"30 of SEBI Listing Regulations - Execution of deed of Corporate Guarantee.\",\"category\":\"Giving guarantees\/indemnity\/ becoming a surety for third party\",\"date\":\"05-Aug-2026 16:30:58\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/NEULANDLAB_05082026163040_SignedSEIntimation.pdf\",\"headline\":\"Company update\",\"impact\":\"This is a recent company development worth monitoring. It should not automatically be treated as the sole cause of today's price move.\",\"importance_score\":2,\"completeness_score\":3}],\"insider_activity\":[{\"person\":\"Davuluri Saharsh Rao\",\"category\":\"Promoters\",\"type\":\"Pledge\",\"quantity\":\"96000\",\"post_holding\":\"195125\",\"date\":\"25-Mar-2026\",\"mode\":\"Pledge Creation\",\"source\":\"NSE PIT disclosure\"},{\"person\":\"Deepthi Davuluri\",\"category\":\"Promoter Group\",\"type\":\"Buy\",\"quantity\":\"12500\",\"post_holding\":\"12500\",\"date\":\"04-Mar-2026\",\"mode\":\"Gift\",\"source\":\"NSE PIT disclosure\"},{\"person\":\"Davuluri Saharsh Rao\",\"category\":\"Promoters\",\"type\":\"Sell\",\"quantity\":\"12500\",\"post_holding\":\"195125\",\"date\":\"04-Mar-2026\",\"mode\":\"Gift\",\"source\":\"NSE PIT disclosure\"},{\"person\":\"Mr. Gannabathula Venkata Krishna Rama Rao\",\"category\":\"Promoters\",\"type\":\"Sell\",\"quantity\":\"6000\",\"post_holding\":\"6627\",\"date\":\"17-Dec-2025\",\"mode\":\"Gift\",\"source\":\"NSE PIT disclosure\"},{\"person\":\"Ms. Kamala Tayaramma Kommula\",\"category\":\"Promoter Group\",\"type\":\"Buy\",\"quantity\":\"6000\",\"post_holding\":\"6000\",\"date\":\"17-Dec-2025\",\"mode\":\"\",\"source\":\"NSE PIT disclosure\"}],\"promoter_pledge\":{\"summary\":\"Recent NSE pledge\/encumbrance disclosures: Davuluri Saharsh Rao: Pledge \u2014 96000 shares (25-Mar-2026)\",\"events\":[{\"person\":\"Davuluri Saharsh Rao\",\"category\":\"Promoters\",\"type\":\"Pledge\",\"quantity\":\"96000\",\"post_holding\":\"195125\",\"date\":\"25-Mar-2026\",\"mode\":\"Pledge Creation\",\"source\":\"NSE PIT disclosure\"}],\"source\":\"NSE PIT disclosure\"},\"shareholding_snapshot\":{\"promoter_pct\":32.26,\"public_pct\":67.74,\"fii_pct\":21.93,\"dii_pct\":16.26,\"mf_pct\":12.45,\"institutional_pct\":38.19,\"noninst_pct\":29.55,\"mf_scheme_count\":34,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"HDFC MUTUAL FUND - HDFC MNC FUND\",\"shares\":361972,\"pct\":2.82},{\"name\":\"HSBC MUTUAL FUND - HSBC SMALL CAP FUND\",\"shares\":198512,\"pct\":1.55},{\"name\":\"ICICI PRUDENTIAL S&amp;P BSE 500 ETF\",\"shares\":196099,\"pct\":1.53},{\"name\":\"MAHINDRA MANULIFE ELSS TAX SAVER FUND\",\"shares\":195650,\"pct\":1.52}],\"period\":\"30-SEP-2026\",\"submission_date\":\"12-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1736092_12102026034744_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":32.62,\"previous_fii_pct\":21.08,\"previous_dii_pct\":16.51,\"previous_mf_pct\":12.66,\"previous_institutional_pct\":37.59,\"previous_mf_scheme_count\":32,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"brokerage_views\":[{\"brokerage\":\"Goldman Sachs\",\"rating\":\"Buy\",\"target\":null,\"view_summary\":\"Goldman Sachs Retains 'Buy' On Neuland Labs After Q4 Performance Exceeds Estimates, Hikes Target Price NDTV Profit\",\"headline\":\"Goldman Sachs Retains 'Buy' On Neuland Labs After Q4 Performance Exceeds Estimates, Hikes Target Price\",\"published\":\"2026-05-13T07:00:00+00:00\",\"source\":\"NDTV Profit\"},{\"brokerage\":\"Nuvama\",\"rating\":\"Buy\",\"target\":null,\"view_summary\":\"Mukul Agrawal's top holdings: Nuvama, J&K Bank, Radico, Neuland & more \u2014 Should you buy?\",\"headline\":\"Mukul Agrawal's top holdings: Nuvama, J&K Bank, Radico, Neuland & more \u2014 Should you buy?\",\"published\":\"2026-05-13T07:00:00+00:00\",\"source\":\"Business Today\"}],\"bulk_block_deals\":[{\"deal_type\":\"Bulk\",\"date\":\"06 Aug, 2026\",\"party\":\"HDFC MUTUAL FUND\",\"side\":\"Buy\",\"quantity\":\"64,547\",\"price\":\"21,585\",\"value\":\"\u20b9139.32 Cr\",\"source\":\"NSE-reported large-deal disclosure\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Neuland Laboratories share price rose 1.01% to \u20b919,055.00 today. See why NEULANDLAB is rising, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":8681,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Neuland Laboratories Share Price Today: Why NEULANDLAB Is Rising 1.01% | 26 October 2026","_witty_meta_description":"Neuland Laboratories share price rose 1.01% to \u20b919,055.00 today. See why NEULANDLAB is rising, volume context, company developments and what to watch next.","_witty_primary_phrase":"Neuland Laboratories share price today","_witty_reason_label":"technical rebound following recent sector-aligned buying","_witty_reason_confidence":"low","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[262],"class_list":["post-8682","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-neulandlab"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/8682","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=8682"}],"version-history":[{"count":2,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/8682\/revisions"}],"predecessor-version":[{"id":8831,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/8682\/revisions\/8831"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/8681"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=8682"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=8682"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=8682"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}